BiotechTube

Bleomycin sulfate + Vincristine sulfate + Doxorubicin hydrochloride + Zalcitabine + Didanosine

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sarcoma, Kaposi

Conditions

Sarcoma, Kaposi, HIV Infections

Trial Timeline

— → Sep 1, 1996

NCT ID
NCT00000954

About Bleomycin sulfate + Vincristine sulfate + Doxorubicin hydrochloride + Zalcitabine + Didanosine

Bleomycin sulfate + Vincristine sulfate + Doxorubicin hydrochloride + Zalcitabine + Didanosine is a phase 1 stage product being developed by Bristol Myers Squibb for Sarcoma, Kaposi. The current trial status is completed. This product is registered under clinical trial identifier NCT00000954. Target conditions include Sarcoma, Kaposi, HIV Infections.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00000954Phase 1Completed

Competing Products

20 competing products in Sarcoma, Kaposi

See all competitors
ProductCompanyStageHype Score
Tc99m-tilmanoceptNavidea BiopharmaceuticalsPhase 1
25
Azenosertib + GemcitabineZentalis PharmaceuticalsPhase 1/2
33
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
33
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 1/2
33
AbemaciclibEli LillyPhase 2
52
Abemaciclib + PlaceboEli LillyPhase 3
77
cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acidChugai PharmaceuticalPhase 3
77
PLX3397 + sirolimusDaiichi SankyoPhase 1/2
41
exatecan mesylateDaiichi SankyoPhase 2
52
efatutazoneDaiichi SankyoPhase 2
52
soblidotinDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
LinsitinibAstellas PharmaPhase 2
52
Fluzoparib+ DalpiciclibSun PharmaceuticalPhase 2
52
Anlotinib HydrochlorideSun PharmaceuticalPhase 2
52
Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+VincristineSun PharmaceuticalPhase 2
52
irinotecan liposome (II) + temozolomide + fluzoparibSun PharmaceuticalPhase 2
52
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
77
EribulinEisaiPhase 2
52
Lenvatinib + Ifosfamide + Etoposide + LenvatinibEisaiPhase 2
52

Other Products from Bristol Myers Squibb

DeucravacitinibApproved
84
Aripiprazole + Olanzapine + HaloperidolApproved
84
Irbesartan + CiprofibrateApproved
84
Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved
84
deucravacitinibApproved
84